Teriflunomide in multiple sclerosis: an update

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

Teriflunomide, a once-daily, oral disease-modifying therapy, has demonstrated efficacy in patients with relapsing forms of multiple sclerosis (MS) and patients with a first clinical episode suggestive of MS. As the only disease-modifying therapy with positive disability results in two Phase III trials, teriflunomide significantly slowed disability in patients with relapsing forms of MS. We highlight data from the Phase II study and the TEMSO, TOWER, TOPIC and TENERE teriflunomide studies. TEMSO MRI outcomes have been supported with Structural Image Evaluation Using Normalization of Atrophy analyses. We present data from long-term extensions of the Phase II study, TEMSO and TOWER, as well as results from patients who switched from other disease-modifying therapies to teriflunomide, patient-reported outcomes and supplementary measures of response.

Original languageEnglish
Pages (from-to)9-29
Number of pages21
JournalNeurodegenerative Disease Management
Volume7
Issue number1
DOIs
StatePublished - 1 Feb 2017

Keywords

  • clinical trials
  • disease-modifying therapy
  • drug development
  • multiple sclerosis
  • teriflunomide

Fingerprint

Dive into the research topics of 'Teriflunomide in multiple sclerosis: an update'. Together they form a unique fingerprint.

Cite this